Literature DB >> 10618532

Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection.

D I Bernstein1.   

Abstract

To evaluate the effects of the route of vaccination on protection against genital HSV infection guinea pigs were vaccinated twice with vaccinia recombinants expressing HSV-2 glycoprotein D or controls by intradermal, intranasal or intravaginal inoculation. Following HSV-2 intravaginal challenge, immunization by all 3 routes reduced vaginal HSV shedding and acute genital disease. The intravaginal vaccination, however, most effectively reduced primary and recurrent HSV disease. Vaccinia and HSV antibody titers were similar in all vaccinia gD immunized groups while the lymphoproliferative response was highest in the intradermal group. In a smaller follow-up experiment we demonstrated that intrarectal immunization with vaccinia gD could also induce antibody and T cell responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618532     DOI: 10.1016/s0264-410x(99)00416-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.

Authors:  Janina Q Jiang; Amy Patrick; Ronald B Moss; Kenneth L Rosenthal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 2.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.

Authors:  Robert J Natuk; David Cooper; Min Guo; Priscilla Calderon; Kevin J Wright; Farooq Nasar; Susan Witko; Diane Pawlyk; Margaret Lee; Joanne DeStefano; Donna Tummolo; Aaron S Abramovitz; Seema Gangolli; Narender Kalyan; David K Clarke; R Michael Hendry; John H Eldridge; Stephen A Udem; Jacek Kowalski
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

Review 5.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 6.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

7.  A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.

Authors:  Kening Wang; Kyle N Goodman; Daniel Y Li; Mark Raffeld; Mayra Chavez; Jeffrey I Cohen
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

8.  Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.

Authors:  Josefine Persson; Yuan Zhang; Thorunn A Olafsdottir; Karolina Thörn; Tina M Cairns; Frank Wegmann; Quentin J Sattentau; Roselyn J Eisenberg; Gary H Cohen; Ali M Harandi
Journal:  Front Immunol       Date:  2016-12-26       Impact factor: 7.561

9.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.